文献速递系统性红斑狼疮

巴瑞替尼在活动性系统性红斑狼疮患者中的作用机制及生物标志物与关键免疫通路的识别

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.
PubMed 文献 · Ann Rheum Dis · 2022-08-11

该II期随机安慰剂对照研究纳入239例接受标准背景治疗的活动性SLE患者(巴瑞替尼2mg组88例、4mg组82例、安慰剂组69例)及49例健康对照,采用Olink靶向炎症面板检测基线及第12周血清分析物。结果显示巴瑞替尼4mg较安慰剂显著降低CCL19、CXCL10、TNF-α、TNFRSF9/CD137、PD-L1、IL-6和IL-12β,作者认为其可能通过多靶点机制下调SLE中上调的关键细胞因子。

要点

  • 巴瑞替尼4mg较安慰剂在第12周显著降低CCL19、CXCL10、TNF-α、TNFRSF9/CD137、PD-L1、IL-6和IL-12β。
  • 炎症生物标志物与I型干扰素、抗dsDNA及疾病活动度、关节计数和关节疼痛存在相关性/关联。
  • 作者认为巴瑞替尼4mg可能发挥超越干扰素特征的多靶点机制,临床相关性尚待进一步阐明。

核心结论

  • 作者认为巴瑞替尼4mg下调了SLE患者中上调的关键细胞因子,可能发挥超越干扰素特征的多靶点机制,但临床相关性尚待进一步阐明。

研究设计与样本

  • II期随机安慰剂对照研究,纳入接受标准背景治疗的成人SLE患者,巴瑞替尼2mg组88例、4mg组82例、安慰剂组69例,另设49例健康对照。
  • 基线及第12周采集血清,采用邻位延伸分析(Target 96 Inflammation Panel,Olink)检测,干扰素评分采用mRNA面板测定。
  • 采用基于限制性最大似然的重复测量混合模型比较第12周较基线的变化,并计算Spearman相关性。

主要发现

  • 基线时SLE血清相对健康对照血清存在强烈细胞因子失调。
  • 第12周巴瑞替尼4mg组较安慰剂组CCL19、CXCL10、TNF-α、TNFRSF9/CD137、PD-L1、IL-6和IL-12β显著降低。
  • 炎症生物标志物与I型干扰素(CCL19、CXCL10、TNF-α和PD-L1)、抗dsDNA(TNF-α、CXCL10)及SLEDAI-2000、压痛和肿胀关节计数、最严重关节疼痛(CCL19、IL-6和TNFRSF9/CD137)存在相关性/关联。

关键数值与推荐

  • 巴瑞替尼4mg组较安慰剂组第12周CCL19、CXCL10、TNF-α、TNFRSF9/CD137、PD-L1、IL-6和IL-12β显著降低。
  • 巴瑞替尼2mg组88例、4mg组82例、安慰剂组69例,健康对照49例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出临床相关性尚待进一步阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To elucidate the mechanism of action of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, and describe immunological pathways related to disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II trial. METHODS: Patients with SLE were treated with baricitinib 2 mg or 4 mg in a phase II randomised, placebo-controlled study. Sera from 239 patients (baricitinib 2 mg: n=88; baricitinib 4 mg: n=82; placebo: n=69) and 49 healthy controls (HCs) were collected at baseline and week 12 and analysed using a proximity extension assay (Target 96 Inflammation Panel (Olink)). Interferon (IFN) scores were determined using an mRNA panel. Analytes were compared in patients with SLE versus HCs and in changes from baseline at week 12 between baricitinib 2 mg, 4 mg and placebo groups using a restricted maximum likelihood-based mixed models for repeated measures. Spearman correlations were computed for analytes and clinical measurements. RESULTS: At baseline, SLE sera had strong cytokine dysregulation relative to HC sera. C-C motif chemokine ligand (CCL) 19, C-X-C motif chemokine ligand (CXCL) 10, tumour necrosis factor alpha (TNF-α), TNF receptor superfamily member (TNFRSF)9/CD137, PD-L1, IL-6 and IL-12β were significantly reduced in patients treated with baricitinib 4 mg versus placebo at week 12. Inflammatory biomarkers indicated correlations/associations with type I IFN (CCL19, CXCL10, TNF-α and PD-L1), anti-double stranded DNA (dsDNA) (TNF-α, CXCL10) and Systemic Lupus Erythematosus Disease Activity Index-2000, tender and swollen joint count and worst joint pain (CCL19, IL-6 and TNFRSF9/CD137). CONCLUSION: These results suggest that baricitinib 4 mg downregulated key cytokines that are upregulated in patients with SLE and may play a role in a multitargeted mechanism beyond the IFN signature although clinical relevance remains to be further delineated. TRIAL REGISTRATION NUMBER: NCT02708095.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Dörner T, Tanaka Y, Dow ER, et al. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022. PMID: 35609978. doi:10.1136/annrheumdis-2022-222335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。